EFFICACY OF XT-150, A NOVEL NON-VIRAL GENE THERAPY DELIVERING IL-10v, ON MODERATE TO SEVERE PAIN DUE TO KNEE OSTEOARTHRITIS: PATIENT SUBGROUP ANALYSIS

Purpose (the aim of the study): Interleukin (IL)-10 is a regulator of cytokine activity and has the potential to restore homeostasis in osteoarthritis (OA) of the knee. XT-150 is a non-viral gene therapy designed to durably express a proprietary variant of the anti-inflammatory cytokine IL-10 (IL-10v). XT-150-2-0204 (NCT04124042) evaluated the safety and efficacy of single and repeat intra-articular (IA) doses of XT-150 in patients with moderate-severe knee OA. The purpose of this analysis was to evaluate the efficacy findings based on baseline demographic subgroups.